HOME > Investors >
Press Releases
2017-11-17
ViroMed Builds Team of Experts to Complete New Global Drug Development
2017-11-06
VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM202
2017-10-16
2017.09(IR letter) BusinessUpdates
2017-10-12
ViroMed, VM202 Phase III for CLI Approved in China
2017-09-25
ViroMed, Gene Therapy Powerhouse on Global Stage
1
2
3
4
5
6
7
8
9
10
